These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

390 related items for PubMed ID: 8433882

  • 21. Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathy: immune mechanisms and update on current therapies.
    van der Meché FG, van Doorn PA.
    Ann Neurol; 1995 May; 37 Suppl 1():S14-31. PubMed ID: 8968214
    [Abstract] [Full Text] [Related]

  • 22. Treatment of immune-mediated, dysimmune neuropathies.
    Finsterer J.
    Acta Neurol Scand; 2005 Aug; 112(2):115-25. PubMed ID: 16008538
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. EFNS guidelines for the use of intravenous immunoglobulin in treatment of neurological diseases: EFNS task force on the use of intravenous immunoglobulin in treatment of neurological diseases.
    Elovaara I, Apostolski S, van Doorn P, Gilhus NE, Hietaharju A, Honkaniemi J, van Schaik IN, Scolding N, Soelberg Sørensen P, Udd B, EFNS.
    Eur J Neurol; 2008 Sep; 15(9):893-908. PubMed ID: 18796075
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Intravenous immune globulin in myasthenia gravis.
    Gajdos P.
    Clin Exp Immunol; 1994 Jul; 97 Suppl 1(Suppl 1):49-51. PubMed ID: 8033435
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Can we face the challenge of expanding use of intravenous immunoglobulin in neurology?
    Elovaara I, Hietaharju A.
    Acta Neurol Scand; 2010 Nov; 122(5):309-15. PubMed ID: 20085560
    [Abstract] [Full Text] [Related]

  • 32. Immunomodulation of autoimmune and inflammatory diseases with intravenous immunoglobulin.
    Ephrem A, Misra N, Hassan G, Dasgupta S, Delignat S, Duong Van Huyen JP, Chamat S, Prost F, Lacroix-Desmazes S, Kavery SV, Kazatchkine MD.
    Clin Exp Med; 2005 Dec; 5(4):135-40. PubMed ID: 16362793
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Intravenous immunoglobulin for treatment of neuromuscular disease.
    Ruzhansky K, Brannagan TH.
    Neurol Clin Pract; 2013 Oct; 3(5):440-445. PubMed ID: 29473612
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Use of intravenous gamma globulins in neuroimmunologic diseases.
    Latov N, Chaudhry V, Koski CL, Lisak RP, Apatoff BR, Hahn AF, Howard JF.
    J Allergy Clin Immunol; 2001 Oct; 108(4 Suppl):S126-32. PubMed ID: 11586280
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Safety of intravenous immune globulin in an outpatient setting for patients with neuromuscular disease.
    Waheed W, Ayer GA, Jadoo CL, Badger GJ, Aboukhatwa M, Brannagan TH, Tandan R.
    Muscle Nerve; 2019 Nov; 60(5):528-537. PubMed ID: 31443119
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 20.